ADMA Biologics (NASDAQ:ADMA) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

ADMA has been the topic of a number of other research reports. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA opened at $16.38 on Monday. ADMA Biologics has a 1 year low of $13.50 and a 1 year high of $25.67. The stock has a market capitalization of $3.90 billion, a price-to-earnings ratio of 27.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The company’s 50 day simple moving average is $17.13 and its 200 day simple moving average is $16.80.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. During the same period in the prior year, the company earned $0.46 earnings per share. The company’s quarterly revenue was up 18.4% on a year-over-year basis. As a group, research analysts predict that ADMA Biologics will post 0.51 EPS for the current fiscal year.

Institutional Trading of ADMA Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC raised its holdings in ADMA Biologics by 58.0% in the 4th quarter. Corient Private Wealth LLC now owns 91,367 shares of the biotechnology company’s stock valued at $1,667,000 after buying an additional 33,541 shares during the last quarter. Vident Advisory LLC increased its position in ADMA Biologics by 24.2% in the 4th quarter. Vident Advisory LLC now owns 270,492 shares of the biotechnology company’s stock valued at $4,934,000 after acquiring an additional 52,687 shares during the period. First Citizens Bank & Trust Co. raised its stake in shares of ADMA Biologics by 24.4% during the fourth quarter. First Citizens Bank & Trust Co. now owns 48,763 shares of the biotechnology company’s stock valued at $889,000 after acquiring an additional 9,576 shares during the last quarter. Cim LLC raised its stake in shares of ADMA Biologics by 3.2% during the fourth quarter. Cim LLC now owns 94,379 shares of the biotechnology company’s stock valued at $1,721,000 after acquiring an additional 2,893 shares during the last quarter. Finally, nVerses Capital LLC acquired a new position in shares of ADMA Biologics during the fourth quarter worth $395,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.